Perrigo announced it has received final approval for its abbreviated New Drug Application (ANDA) for Fluocinonide Cream 0.1%, the generic version of MedicisVanos Cream.

RELATED: Dermatological Disorders Resource Center

Fluocinonide is a topical corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients >12 years of age. Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation.

Perrigo had resolved litigation with the brand and has commenced shipment of the product with 180 days of generic exclusivity.

For more information call (866) 634-9120 or visit